(IN BRIEF) GSK’s Shingrix vaccine has been approved by China’s NMPA for adults aged 18 and over who are immunocompromised or immunosuppressed, marking the first shingles vaccine available for this group in the country. Affecting about six million people annually … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged CHINA, China National Medical Products Administration, clinical studies, global health, GSK, GSK Expands Shingrix Approval in China to Include Immunocompromised Adults at Risk of Shingles, GSK Strengthens Vaccine Portfolio with Shingrix Approval for High-Risk Adult Populations in China, GSK Wins China Approval for Shingrix in Immunocompromised Adults Expanding Protection Against Shingles, Healthcare, herpes zoster, immunocompromised adults, immunodeficiency, immunosuppression, infectious diseases, NMPA, preventive medicine, public health, Recombinant Zoster Vaccine, RZV, Sanjay Gurunathan, Shingles, Shingrix, vaccine approval, Vaccine Innovation
(IN BRIEF) The European Investment Bank and European Commission are jointly supporting BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, with up to €95 million in blended financing. The project aims to strengthen Africa’s capacity to produce vaccines locally for diseases … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Technology
Tagged Africa CDC, African Union, and CEPI Join Forces to Strengthen Africa’s Vaccine Independence Through BioNTech’s Kigali mRNA Facility, BioNTech, BioNTech Secures up to €95 Million in EU and EIB Financing to Boost Vaccine Manufacturing Capacity in Kigali, biotechnology, CEPI, Dr Amadou Sall, EIB, EU, European Commission, European Investment Bank, Global Gateway, HIV, Jozef Sikela, Karl Nehammer, Kigali, local production, malaria, mpox, mRNA Vaccines, public health, Rwanda, Sierk Poetting, Sustainable Healthcare, Team Europe, tuberculosis, Vaccine Innovation, vaccine manufacturing
(IN BRIEF) Sanofi has launched early global shipments of Beyfortus (nirsevimab) in anticipation of the 2025–2026 RSV season, enabling healthcare providers to begin immunizations well before the typical onset of infections in November. In collaboration with AstraZeneca, Sanofi has significantly … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AstraZeneca, Beyfortus, EU label, extended protection, global distribution, hospitalizations, infant immunization, lower respiratory tract disease, monoclonal antibody, newborn care, nirsevimab, pediatric health, public health, real-world studies, respiratory syncytial virus, RSV, RSV season, Sanofi, Thomas Triomphe, Vaccine Innovation, vaccine supply chain
(IN BRIEF) GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new version, expected to be available from January 2025, eliminates the need for reconstitution, offering a … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged administration, adults 50 and over, antigen, AS01B adjuvant system, chickenpox, FDA, glycoprotein E, GSK, healthcare community, healthcare professionals, immune response, immunodeficiency, immunosuppression, liquid adjuvant, lyophilised, non-live vaccine, Prefilled Syringe, recombinant subunit vaccine, Recombinant Zoster Vaccine, reconstitution, RZV, safety, Shingles, shingles prevention, shingles vaccine, Shingrix, Shingrix approval, vaccine composition, Vaccine Innovation, vaccine presentation, vaccine safety, varicella, varicella-zoster virus
(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, and COVID-19. The company revealed promising data across its portfolio, including Beyfortus, an antibody … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Beyfortus, COVID-19, FluMist, hMPV, IDWeek 2024, Iskra Reic, IVX-A12, Respiratory Disease Prevention, RSV, safety, Vaccine Innovation
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?